BRK”ing” Down All We Know About PTK6 in Breast Cancer

Yi Yuan, Hui Li Ang, Xianning Lai, Lingzhi Wang, Vijay Pandey, Benjamin BoJun Huang, Tuan Zea Tan, Hui Yi Chong, Philip Zheng Yang Ong, Kanchugarakoppal S. Rangappa, Frank Arfuso, Kevin Tan, Basappa Basappa, Boon Cher Goh, Ruby Yun‐Ju Huang, Gautam Sethi, Peter E. Lobie, Alan Prem KumarPreprints.org 2018 · DOI

Abstract

The search for improved therapeutic approaches to breast cancer are still on going. Breast tumor kinase (BRK, also known as PTK6) is one of the targets, it is highly expressed in breast carcinomas while displaying low or no expression in the normal mammary gland, which hints at the oncogenic role of this enzyme in breast cancer. In these twenty years, an increasing number of studies have focused on understanding the cellular roles of BRK in breast cancers. This review outlines the advances made towards understanding the cellular and physiological role of BRK, the molecular and chemical inhibitors and its therapeutic significance in breast cancer.
BibTeX
@misc{yuan2018brk,
  author = {Yi Yuan and Hui Li Ang and Xianning Lai and Lingzhi Wang and Vijay Pandey and Benjamin BoJun Huang and Tuan Zea Tan and Hui Yi Chong and Philip Zheng Yang Ong and Kanchugarakoppal S. Rangappa and Frank Arfuso and Kevin Tan and Basappa Basappa and Boon Cher Goh and Ruby Yun‐Ju Huang and Gautam Sethi and Peter E. Lobie and Alan Prem Kumar},
  title = {{BRK\”ing\” Down All We Know About PTK6 in Breast Cancer}},
  year = {2018},
  doi = {10.20944/preprints201808.0044.v1},
  howpublished = {Preprints.org},
}

Loading related content...

Figure